WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to...
ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a...
SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast...
Toronto, Ontario--(Newsfile Corp. - April 7, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9) ("FSD Pharma" or...
TORONTO, ON / ACCESSWIRE / April 5, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
New development pathway significantly expands addressable patient population for IV Choline ChlorideIV Choline Chloride has the potential to become the...
LONDON, UK / ACCESSWIRE / April 4, 2024 / The UK is ‘in the grip of the worst heart care...
Clinical Data from Multiple Trials Showed Improvements in Both Motor and Non-Motor SymptomsJERUSALEM and BURLINGTON, Mass., April 04, 2024 (GLOBE...
STOCKHOLM, SE / ACCESSWIRE / April 4, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...
Boston, Massachusetts--(Newsfile Corp. - April 3, 2024) - Social Impact Partners is proud to announce the successful conclusion of the...
ANAHEIM, CA, April 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer of...
Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial HypertensionBOSTON and ATLANTA, April 03, 2024...
STOCKHOLM, SWEDEN / ACCESSWIRE / April 3, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...
OKLAHOMA CITY, April 2, 2024 /PRNewswire/ -- In a momentous occasion, Oklahoma Proton Center, a leading provider of cutting-edge proton...
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system...
Previously served as Acting General Counsel to the Department of Veterans AffairsHOUSTON, TEXAS, April 02, 2024 (GLOBE NEWSWIRE) -- Nexalin...
Expect Topline Data for Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab for Alzheimer’s Disease in Q3 2024 Company raised $17.9 million...
TORONTO, ON / ACCESSWIRE / April 1, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
Lead program, Berubicin, successfully passed pre-planned interim futility analysis milestone with recommendation from DSMB to proceed without modification in potentially...
Transitioned from Pre-Clinical to Clinical Stage company in FY 2023Phase 1/2a trial, designed to assess both healthy volunteers and patients...